Stroke Prevention in Atrial Fibrillation: Current Status and Near-Future Directions

被引：15

作者：

De Caterina, Raffaele ^{[1
,2
]}

Hylek, Elaine M. ^{[3
]}

机构：

[1] Univ G DAnnunzio, Inst Cardiol, Chieti, Italy

[2] Univ G DAnnunzio, Ctr Excellence Aging, Chieti, Italy

[3] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA

来源：

AMERICAN JOURNAL OF MEDICINE | 2011年 / 124卷 / 09期

基金：

美国国家卫生研究院;

关键词：

Anticoagulants; Antithrombotic therapy; Atrial fibrillation; Stroke; Thromboembolism; CLOPIDOGREL PLUS ASPIRIN; VITAMIN-K ANTAGONIST; EURO HEART SURVEY; RISK STRATIFICATION; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULATION; PREDICTING STROKE; ELDERLY-PATIENTS; CLINICAL-TRIALS; WARFARIN;

D O I：

10.1016/j.amjmed.2011.03.013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Prevention of atrial fibrillation-related stroke is an important part of atrial fibrillation management. However, stroke risk is not homogeneous and varies with associated morbidities and risk factors. Risk stratification schemes have been developed that categorize patients' stroke risk into classes based on a combination of risk factors. According to the calculated level of risk, guidelines recommend patients with atrial fibrillation receive antithrombotic therapy either as a vitamin K antagonist or aspirin. Despite recommendations, however, many patients with atrial fibrillation do not receive adequate thromboprophylaxis. We will discuss some of the underlying reasons, in part related to the drawbacks associated with vitamin K antagonists. These highlight the need for new anticoagulants in atrial fibrillation. The novel oral anticoagulants in development may overcome some of the limitations of vitamin K antagonists and address their underuse and safety concerns. (C) 2011 Elsevier Inc. All rights reserved. The American Journal of Medicine (2011) 124, 793-799

引用

页码：793 / 799

页数：7

共 44 条

[11] Anticoagulants in heart disease: current status and perspectives [J].

De Caterina, Raffaele ;

Husted, Steen ;

Wallentin, Lars ;

Agnelli, Giancarlo ;

Bachmann, Fedor ;

Baigent, Colin ;

Jespersen, Jorgen ;

Kristensen, Steen Dalby ;

Montalescot, Gilles ;

Siegbahn, Agneta ;

Verheugt, Freek W. A. ;

Weitz, Jeffrey .

EUROPEAN HEART JOURNAL, 2007, 28 (07) :880-913

[12] Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study [J].

Deplanque, D ;

Leys, D ;

Parnetti, L ;

Schmidt, R ;

Ferro, J ;

De Reuck, J ;

Mas, JL ;

Gallai, V .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (06) :798-806

[13] Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation - Pooled analysis from the SPORTIF III and V studies [J].

Diener, HC .

CEREBROVASCULAR DISEASES, 2006, 21 (04) :279-293

[14] Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment [J].

Eikelboom, John W. ;

O'Donnell, Martin ;

Yusuf, Salim ;

Diaz, Rafael ;

Flaker, Greg ;

Hart, Robert ;

Hohnloser, Stefan ;

Joyner, Campbell ;

Lawrence, Jack ;

Pais, Prem ;

Pogue, Janice ;

Synhorst, David ;

Connolly, Stuart J. .

AMERICAN HEART JOURNAL, 2010, 159 (03) :348-U38

[15] The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation [J].

Ellis, David J. ;

Usman, Mohammed Haris ;

Milner, Peter G. ;

Canafax, Daniel M. ;

Ezekowitz, Michael D. .

CIRCULATION, 2009, 120 (12) :1029-U25

[16] Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation [J].

Fang, Margaret C. ;

Go, Alan S. ;

Chang, Yuchiao ;

Borowsky, Leila ;

Pomernacki, Niela K. ;

Singer, Daniel E. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (08) :810-815

[17] Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation [J].

Flaker, Greg C. ;

Pogue, Janice ;

Yusuf, Salim ;

Pfeffer, Marc A. ;

Goldhaber, Samuel Z. ;

Granger, Christopher B. ;

Anand, Inderjit S. ;

Hart, Robert ;

Connolly, Stuart J. .

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2010, 3 (03) :277-U87

[18] Stroke prophylaxis in atrial fibrillation: who gets it and who does not? [J].

Friberg, Leif ;

Hammar, Niklas ;

Ringh, Mattias ;

Pettersson, Hans ;

Rosenqvist, Marten .

EUROPEAN HEART JOURNAL, 2006, 27 (16) :1954-1964

[19] ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society [J].

Fuster, Valentin ;

Ryden, Lars E. ;

Cannom, David S. ;

Crijns, Harry J. ;

Curtis, Anne B. ;

Ellenbogen, Kenneth A. ;

Halperin, Jonathan L. ;

Le Heuzey, Jean-Yves ;

Kay, G. Neal ;

Lowe, James E. ;

Olsson, S. Bertil ;

Prystowsky, Eric N. ;

Tamargo, Juan Luis ;

Wann, Samuel .

CIRCULATION, 2006, 114 (07) :E257-E354

[20] Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation [J].

Gage, BF ;

Waterman, AD ;

Shannon, W ;

Boechler, M ;

Rich, MW ;

Radford, MJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22) :2864-2870

← 1 2 3 4 5 →